Invests in
Sectors:
Locations:
Min Investment:
$100,000.00Max Investment:
$5,000,000.00Target Investment:
$1,500,000.00
Skills
Education
- HU
- Uo
Lists including Carlo
Investments
Nexo Therapeutics
Total Funding: $60M
Jnana Therapeutics
Total Funding: $160M
Nested Therapeutics
Total Funding: $35M
Stablix
Total Funding: $63M
Graphite Bio
Total Funding: $200M
Century Therapeutics
Total Funding: $470M
Pandion Therapeutics
Total Funding: $140M
Venatorx Pharmaceuticals
Total Funding: $76M
Work Experience
2012
Managing Director
2022
Partner
2012 - 2022
Director, Graphite Bio (GRPH) Director, Century Therapeutics (IPSC) Director, Jnana Therapeutics Director, FirstLight Bio Director, 858 Therapeutics Director, Stablix Director, Nested Therapeutics Director, Pandion Therapeutics (PAND, acquired) Director, Venatorx (2017-2022) Founding CEO, Kyras Therapeutics (2015-2017) Chief Business Officer, Anokion (2014-2017)
2015 - 2022
CEO
2015 - 2022
Highline Therapeutics is a biotech incubator established by Versant Ventures in New York City. Modeled on Blueline Bioscience in Toronto, Highline aims to identify and accelerate translational research and biotech company formation. Highline will partner with both local academic institutions and pharmaceutical companies to help bridge the gap between academic science and the development of novel therapeutics.
2010 - 2012
Global Program Team Director
2010 - 2012
Lead global, cross-functional team developing intelligent medicines by integrating electronics and pharmaceuticals to enable remote patient monitoring/e-health applications
2010 - 2010
Assistant to the CEO
2010 - 2010
2009 - 2010
Assistant to CEO - Pharmaceuticals
2009 - 2010
2002 - 2008
Associate Principal
2002 - 2008
2000 - 2002
Business Development Manager
2000 - 2002